Acute myeloid leukemia in elderly patients: experience of a single center

Show simple item record Rodrigues, Celso Arrais [UNIFESP] Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP] Pelloso, L.a.f. [UNIFESP] Ghaname, F.s. [UNIFESP] Kerbauy, Daniela Márcia Bahia [UNIFESP] Campos, M.g.v. [UNIFESP] Yamamoto, Mihoko [UNIFESP] 2015-06-14T13:30:03Z 2015-06-14T13:30:03Z 2003-06-01
dc.identifier.citation Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 36, n. 6, p. 703-708, 2003.
dc.identifier.issn 0100-879X
dc.description.abstract Acute myeloid leukemia (AML) is a disease predominantly of older adults. Treatment of AML in the elderly is complicated not only by comorbidities but also by the high prevalence of poor prognosis markers. Thirty-one consecutive unselected patients with AML older than 60 years (representing 33% of all AML cases diagnosed at our institution during the same period) were followed over a period of 5 years (1997-2002). A high incidence of AML with multilineage dysplasia (45%) and no favorable cytogenetic abnormalities but 62% intermediate and 38% unfavorable karyotypes were found. Sixteen patients (52%) were selected for induction of intensive cytotoxic treatment and complete remission was achieved only by some of these intensively treated patients (7 of 16). Of these, 3 remained alive without disease (median: 11 months), 1 patient died shortly after complete remission, and 3 patients relapsed and died from refractory disease. Only 1 patient that was refractory to intensive cytotoxic treatment remained alive with disease under supportive care. Fifteen patients (48%) were managed with palliative/supportive care: 7 received palliative treatment and supportive care, 8 received supportive care only, and 4 patients remained alive with disease under supportive care (median: 9 months). Mortality rate was 74% and overall survival at two years was 12%. To the best of our knowledge, there is no previous report regarding elderly patients with AML in Brazilian subsets. The present data are similar to previously reported studies showing that elderly AML patients are not only older but also biologically distinct from younger AML patients, particularly in terms of the high incidence of poor prognostic karyotypes and resistance to therapy. en
dc.format.extent 703-708
dc.language.iso eng
dc.publisher Associação Brasileira de Divulgação Científica
dc.relation.ispartof Brazilian Journal of Medical and Biological Research
dc.rights Acesso aberto
dc.subject Acute myeloid leukemia en
dc.subject Elderly patients en
dc.subject G-banding karyotype en
dc.subject Induction therapy en
dc.subject Overall survival en
dc.title Acute myeloid leukemia in elderly patients: experience of a single center en
dc.type Artigo
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.description.affiliation Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Disciplina de Hematologia e Hemoterapia
dc.description.affiliationUnifesp UNIFESP, EPM, Disciplina de Hematologia e Hemoterapia
dc.identifier.file S0100-879X2003000600004.pdf
dc.identifier.scielo S0100-879X2003000600004
dc.identifier.doi 10.1590/S0100-879X2003000600004
dc.description.source SciELO
dc.identifier.wos WOS:000183866400004


Name: S0100-879X2003000600004.pdf
Size: 486.2Kb
Format: PDF
Open file

This item appears in the following Collection(s)

Show simple item record




My Account